Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 4Phase 3 2

Status

Active not recruiting 3Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Uterine Cervical Neoplasms 6Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Lung Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Neoplasm Metastasis 2Cholangiocarcinoma 2Vulvar Neoplasms 1Vaginal Neoplasms 1Urothelial Bladder Carcinoma 1Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thymoma 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Oligometastatic Prostate Cancer 1Neoplasms 1Metastatic Urothelial Cancer 1Melanoma 1Locally Advanced Pancreatic Cancer 1Locally Advanced Cervical Cancer 1Liver Neoplasms 1Liposarcoma 1Kidney Neoplasms 1Gestational Trophoblastic Disease 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

Carboplatin 361Pemetrexed 276Cisplatin 230Paclitaxel 213Docetaxel 205Gemcitabine 160Erlotinib Hydrochloride 150Bevacizumab 132pembrolizumab 129Radiotherapy 114Nivolumab 88durvalumab 84Drug Therapy 84osimertinib 82atezolizumab 58Vinorelbine 53Gefitinib 53Radiosurgery 50Cetuximab 39Taxes 37130-nm albumin-bound paclitaxel 36Ipilimumab 34anlotinib 33Surgical Procedures, Operative 33Magnetic Resonance Spectroscopy 33Etoposide 30Albumin-Bound Paclitaxel 29tislelizumab 27icotinib 27aflutinib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Non-Small-Cell Lung × zimberelimab × Clear all
NCT04736173 2026-06-01

ARC-10

Arcus Biosciences, Inc.

Phase 2 Active not recruiting
169 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05633667 2026-06-01

VELOCITY-Lung

Gilead Sciences

Phase 2 Active not recruiting
192 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04791839 2026-05-06

Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer

Washington University School of Medicine

Phase 2 Active not recruiting
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04262856 2025-08-26

ARC-7

Arcus Biosciences, Inc.

Phase 2 Completed
151 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡